Evaluate Safety as Mono or Combination Therapies With Anti-diabetes Mellitus Drugs in Japanese Subjects With Type 2 Diabetes Mellitus
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 728 participants.
Also called NCT01294436
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 728 participants
- Sponsor
- Registry
-
NCT01294436
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Japan
- Registry status
- Completed
Technical summary
Registry record NCT01294436. Allocation not applicable; no masking; primary purpose treatment. Start 2011-02 (registry gives no type); primary completion 2012-09 (actual). Results posted on 2013-09-16.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Evaluate Safety as Mono or Combination Therapies With Anti-diabetes Mellitus Drugs in Japanese Subjects With Type 2 Diabetes Mellitus
- Condition
- Type2 Diabetes
- Condition
- High Blood Sugar
- Intervention (Drug)
- Dapagliflozin
- Lead sponsor
- AstraZeneca
- Collaborator
- Bristol-Myers Squibb
Record details
- Record id
cardio:ct-nct01294436- Content hash
d85ebb33124034592d3db826a0d6879a21a74e9d723cd552e455c138b24f03ac